Immupharma PLC Result of Retail Offer and Director Shareholding (6396L)

TIDMIMM

RNS Number : 6396L

Immupharma PLC

07 September 2023

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, OR INTO OR WITHIN THE UNITED STATES, AUSTRALIA, NEW ZEALAND, CANADA, SOUTH AFRICA OR JAPAN, OR ANY MEMBER STATE OF THE EEA, OR ANY OTHER JURISDICTION WHERE, OR TO ANY OTHER PERSON TO WHOM, TO DO SO MIGHT CONSTITUTE A VIOLATION OR BREACH OF ANY APPLICABLE LAW OR REGULATION. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.

7 September 2023

ImmuPharma Plc

("ImmuPharma" or the "Company")

Result of Retail Offer and Director Shareholding

ImmuPharma Plc is pleased to announce that further to the Company's announcement at 7:02 a.m. on 31 August 2023, the Company has conditionally raised gross proceeds of GBP130,683 through the issue of 6,534,150 New Ordinary Shares at a price of 2 pence to existing retail investors of the Company, via the Winterflood Retail Access Platform ("WRAP"), in addition to the GBP1.35 million raised in the Subscription and Direct Subscription.

An application has been made to the London Stock Exchange for the 6,534,150 new Ordinary Shares to be admitted to trading on AIM. Admission is expected to take place, and dealings on AIM in the Retail Offer Shares are expected to commence, at 8.00 a.m. on or around 12 September 2023.

Director Dealing

Lisa Baderoon, Director, subscribed for 1,000,000 Retail Offer Shares in the Retail Offer. Following Admission, Lisa Baderoon's shareholding will be 1,583,963 Ordinary Shares comprising 0.38% of the issued share capital.]

Total Voting Rights

Following Admission, the Company will have 416,437,265 Ordinary Shares in issue. Since the Company currently holds no shares in treasury, the total number of voting rights in the Company will therefore be 416,437,265. These figures may therefore be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

Capitalised terms used but not defined in this announcement have the same meanings as set out in the announcement of the Company at 7:02 a.m. on 31 August 2023.

For Further Information

 
 ImmuPharma plc 
 Tim McCarthy, Chief Executive 
  Officer 
  Lisa Baderoon, Head of Investor                 [phone] 
  Relations                                       + 44 (0) 7721 413496 
 
   Stanford Capital Partners 
 Patrick Claridge 
  Bob Pountney                                    [phone] 
 
 SPARK Advisory Partners Limited                  [phone] 
 Neil Baldwin                                     [phone] 
 
 Winterflood Retail Access Platform               [e-mail] 
 Alex Skrine, Head of Electronic 
  Trading                                         [phone] 
 Phoebe Pankhurst, Corporate 
  Finance 
  Haris Khawaja, Corporate Finance 
 

Further information on the Company can be found on its website at https://www.immupharma.co.uk/

The Company's LEI is 213800VZKGHXC7VUS895

 
      Details of t he p erson disc harging managerial responsib 
  1    ilities / p erson closely associated 
 a)   Name                        Lisa Baderoon 
     --------------------------  ---------------------------------------- 
      Reason for notification 
  2 
     -------------------------------------------------------------------- 
 a)   Position / status           Director 
     --------------------------  ---------------------------------------- 
 b)   I nitial notification       Initial 
       /Amendment 
     --------------------------  ---------------------------------------- 
      Details of t he issu er, e mission allow a n ce m a r k 
  3    et participan t, au ct ion plat for m, au ction eer or auc 
       tion monitor 
     -------------------------------------------------------------------- 
 a)   Name                        ImmuPharma Plc 
     --------------------------  ---------------------------------------- 
 b)   LEI                         213800VZKGHXC7VUS895 
     --------------------------  ---------------------------------------- 
      Details of t he t ransact ion (s): section to be re p eated 
  4    for ( i) e a ch type of instr u m e n t; (ii) each type of 
       transac tion; (iii) each date; and ( iv) each place w h ere 
       transactions have b een condu cted 
     -------------------------------------------------------------------- 
 a)   Description of the          Ordinary shares of 1p (GBP0.01) each in 
       financial instrument,       the capital of ImmuPharma plc 
       t ype of instrument         ISIN GB0033711010 
       I d e ntification 
       code 
     --------------------------  ---------------------------------------- 
      Nature of the transaction   Subscription in retail offer 
     --------------------------  ---------------------------------------- 
      Price(s) and volumes(s)      Price(s)    Volume(s) 
                                    GBP0.02     1,000,000 
                                               ---------- 
     --------------------------  ---------------------------------------- 
 d)   Aggregated information 
       - Aggregated volume          1,000,000 
       - Aggregated price           GBP0.02 
     --------------------------  ---------------------------------------- 
 e)   Date of the transaction     7 September 2023 
     --------------------------  ---------------------------------------- 
 f)   Place of the transaction    Outside a trading venue 
     --------------------------  ---------------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCNKABNDBKBCCK

(END) Dow Jones Newswires

September 07, 2023 02:00 ET (06:00 GMT)